Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: virgil vancleave who wrote (496)	11/10/1997 2:48:00 PM
From: Brian Pastor	Read Replies (2) \| Respond to of 998

1) Company has 133mm cash or equiv. and a burn rate of 6mm/yr. That is 2 yrs cash. 2) Insider selling is an interesting point. But since the stock has fallen so far, they probably bought it at a higher point and have little to lose by waiting not to mention what the lack of confidence would do to the issue 3) I think you're right on a potential upside if approved (although a doctor buddy of mine tells me that even if approved, many others are working on therapies for same disease and CEPH's efficacy is highly questionable hence the FDA stalling). BUT if approved, will probably at least see alot of short coverage, if not outright institutional investment (Remeber stock was in early 20s when everyone thought approval was a done deal). However, despite ties, no facts regarding income potential of Myotrophin that I have seen. Again, would not invest until after FDA decision publicized. Good luck to those already in on the long side - Shorts - sorry, can't feel good about those who make their money on the downside.